港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

496.720

-5.792-1.15%

漲家數：6

跌家數：25

平家數：2

市盈率：- -

高：507.303

開：502.573

低：495.158

收：502.512

成交量：8,175.03萬

成交額：18.06億

市值：3,152.73億

流通市值：2,806.09億

資料載入中...

總覽新聞資訊

同源康醫藥－Ｂ(02410)股價上升8.209%，現價港幣$2.9

阿斯达克财经

同源康醫藥-B(02410)：短期股價波動無礙長期邏輯，大股東增持疊加穩中向好基本面打開配置空間

智通财经网

基石藥業－Ｂ(02616)股價下跌8.059%，現價港幣$5.59

阿斯达克财经

德琪醫藥－Ｂ(06996)股價下跌8.406%，現價港幣$3.16

阿斯达克财经

亞盛醫藥(06855)股價下跌5.028%，現價港幣$30.98

阿斯达克财经

港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心創新EGFR-TKI 重磅獲批

啓明醫療(02500.HK)折讓近11%配股兼發可換股債券料籌5億人幣

阿斯达克财经

科濟藥業-B盤中漲近5% 公司香港業務取得重要進展

港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展進一步推進愷力美國際化佈局

和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48

阿斯达克财经

港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序

【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善

深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬

阿斯达克财经

涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理

歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理

第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1574/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.69899","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":164.598608,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666546476","title":"同源康醫藥－Ｂ(02410)股價上升8.209%，現價港幣$2.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2666546476","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666546476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 14:05","pubTimestamp":1789106700,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在下午02:04比前收市价上升8.209%，现股价为港币$2.9。至目前为止，今日最高价为$2.99，而最低价为$2.515。总成交量为613.95万股，总成交金额为港币$1.711千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609111558/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609111558/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1574","159938","BK1515","02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666545362","title":"同源康醫藥-B(02410)：短期股價波動無礙長期邏輯，大股東增持疊加穩中向好基本面打開配置空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2666545362","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666545362?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 13:13","pubTimestamp":1789103634,"startTime":"0","endTime":"0","summary":"近期，在基本面稳中向好、核心品种顺利获批附条件上市、大股东大幅增持情况下，同源康股价却在外部因素与短期市场情绪影响下“砸出洼地”，而这也为长期价值投资者留出了潜在的布局机会。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260911/20260911131405_46437.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260911/20260911131405_46437.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02410","BK1574","BK1161","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666480795","title":"基石藥業－Ｂ(02616)股價下跌8.059%，現價港幣$5.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2666480795","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666480795?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:55","pubTimestamp":1789098900,"startTime":"0","endTime":"0","summary":"[下跌股]基石药业－Ｂ(02616) 股价在上午11:54比前收市价下跌8.059%，现股价为港币$5.59。至目前为止，今日最高价为$5.99，而最低价为$5.59。总成交量为1.111千万股，总成交金额为港币$6.363千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112417/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112417/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666485825","title":"德琪醫藥－Ｂ(06996)股價下跌8.406%，現價港幣$3.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2666485825","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666485825?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:14","pubTimestamp":1789096440,"startTime":"0","endTime":"0","summary":"[下跌股]德琪医药－Ｂ(06996) 股价在上午11:13比前收市价下跌8.406%，现股价为港币$3.16。至目前为止，今日最高价为$3.5，而最低价为$3.16。总成交量为61.25万股，总成交金额为港币$198.37万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112316/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112316/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1574","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666548304","title":"亞盛醫藥(06855)股價下跌5.028%，現價港幣$30.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2666548304","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666548304?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:12","pubTimestamp":1789096320,"startTime":"0","endTime":"0","summary":"[下跌股]亚盛医药(06855) 股价在上午11:12比前收市价下跌5.028%，现股价为港币$30.98。至目前为止，今日最高价为$32.48，而最低价为$30.98。总成交量为147.737万股，总成交金额为港币$4.663千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112308/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112308/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510406","title":"港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心 創新EGFR-TKI 重磅獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510406","media":"智通财经","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:01","pubTimestamp":1789095677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早拉升逾9%，截至发稿，涨9.7%，报2.94港元，成交额963.22万港元。消息面上，同源康医药昨晚公布，董事长、执行董事兼总裁吴豫生告知，于本月8至10日期间，于公开市场购入63.5万股H股，占已发行股本总额约0.17%，总代价约209万港元。公司表示，吴豫生已告知未来可能继续根据市场情况购买股份。此次进一步增持股份彰显对集团未来发展前景的信念及充分信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","09939","BK4585","VXUS","KCAI","BK1161","BK4588","02410","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666101235","title":"啓明醫療(02500.HK)折讓近11%配股兼發可換股債券  料籌5億人幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2666101235","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666101235?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:50","pubTimestamp":1789095000,"startTime":"0","endTime":"0","summary":"启明医疗公布，于昨日交易时段后，与认购人杭州盈智勤(参)号股权投资合伙企业订立协议，将配发1.85亿股待认购股份及本金额不超过3.797亿港元的可转换债券。可转换债券初步转换价为每股转换股份1.1858港元，较前交易日收市价每股1.170港元折让2%。认购事项项下投资总额不超过5亿元人民币，公司拟将所得款项净额用于支付研发、临床及监管费用；补充一般企业营运资金；及偿还未偿还贷款。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201222151856754_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201222151856754_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543983/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543983/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","BK1100","02500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510692","title":"科濟藥業-B盤中漲近5% 公司香港業務取得重要進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510692","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510692?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:42","pubTimestamp":1789094520,"startTime":"0","endTime":"0","summary":"模拟交易客户端科济药业-B盘中涨近5%。科济药业宣布，公司在香港地区的先进疗法产品相关业务取得重要进展，已获得开展相关药剂制品批发供应业务所需的许可资质。此次许可的取得，是科济药业推进恺力美国际化布局的重要里程碑，为公司进一步探索恺力美在香港地区的患者可及路径及相关业务开展奠定了基础，也为公司持续拓展海外市场积累了重要经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-11/doc-inirmmnc5377838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02171","BK1585","BK1587","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517233","title":"港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展 進一步推進愷力美國際化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517233","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517233?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:12","pubTimestamp":1789092731,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1587","BK1574","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457517","title":"和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457517","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457517?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:55","pubTimestamp":1789091700,"startTime":"0","endTime":"0","summary":"[下跌股]和铂医药－Ｂ(02142) 股价在上午09:54比前收市价下跌5.004%，现股价为港币$13.48。至目前为止，今日最高价为$14.01，而最低价为$13.48。总成交量为276.1万股，总成交金额为港币$3.859千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517543","title":"港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517543","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517543?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:49","pubTimestamp":1789091380,"startTime":"0","endTime":"0","summary":"消息面上，先健科技发布公告，于2026年9月9日，本公司收到国家药品监督管理局的正式书面通知，确认由本公司附属公司深圳市健心医疗科技有限公司与国家心血管病中心中国医学科学院阜外医院联合研发的LantvalTM主动脉瓣膜置换系统进入国家药品监督管理局创新医疗器械特别审查程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","KCAI","BK4585","AGNG","HART","GDOC","BK1574","09996","BK1583","01302","LGHT","PTH","LNGR","BK1600","BK1100","159883","IEIH","BK4588","MDEV","VXUS","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666127155","title":"【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2666127155","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666127155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。该机构认为，随着集采影响逐步出清叠加创新驱动和海外业务加速的双重助力，医疗器械板块业绩有望逐步改善。尽管季度业绩增速可能有所波动，Q3能否相比Q2加速尚不确定，但大趋势来看，26和27年年度业绩持续改善的确定性较强。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01066","09996","BK1617","BK1591","BK1583","01302","HART","BK1161","LNGR","BK1189","LU0287142896.SGD","02252","BK1571","RSPH","BK1615","BK1100","02190","02235","06826","BK1247","GDOC","BK1585","601066","BK1589","BK1600","LGHT","BK1587","BK1515","IEIH","PTH","AGNG","BK1501","00241","BK1610","BK0276","KCE","LU0173614495.USD","HK0000165453.HKD","BK1584","00853","MDEV","MEDX","BK1142","BK1222","BK1502","BK1593","159883","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983512","title":"深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983512","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:10","pubTimestamp":1789089045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LGHT","PTH","RSPH","BK1583","BK1507","BK1185","LU0067412154.USD","BK1582","GDOC","HART","MDEV","MEDX","IEIH","00152","BK1100","LU1152091754.HKD","159883","LU1008478684.HKD","09996","LNGR","BK1574","SG9999003461.SGD","LU0880133367.SGD","AGNG","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1997244956.HKD","BK1574","LU2328871848.SGD","06030","09688","BK0028","BK1500","02228","LU1997245177.USD","SG9999014674.SGD","01530","06821","BK1100","LU0634319403.HKD","600030","LU0348827113.USD","CXO","LU0348783233.USD","BK0188","LU1794554557.SGD","SG9999004311.SGD","01789","LU0463099449.HKD","LU2778985437.USD","BK0196","WX","02196","02367","LU1188198961.HKD","01099","BK1593","LU2476274308.USD","LU1969619763.USD","LU1997245094.SGD","LU0244354667.USD","LU0561508036.HKD","LU1146622755.USD","LU2495084118.USD","09926","LU0417516902.SGD","LU0405327494.USD","KCE","KURE","LU0540923850.HKD","03933","BK1521","IE00B3M56506.USD","02268","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275512","title":"歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275512","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088460,"startTime":"0","endTime":"0","summary":"[大手成交]归创通桥(02190)在上午09:01出现大手买入，成交量为85万，成交价为港币$23.4，涉资1.989千万。至目前为止，股价跌1.277%，今日最高价为$23.4，而最低价为$23.4，总成交量为85万股，总成交金额港币$1.989千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","02190","BK1587","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751737","title":"涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751737","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751737?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:17","pubTimestamp":1789085820,"startTime":"0","endTime":"0","summary":"停牌前，拨康视云报1.19港元，较2025年7月上市发行价10.1港元，累计蒸发约88%。这是一间成立于2015年、专注眼科创新药的临床阶段生物科技公司，四次递表才闯关成功，上市首日即告破发，如今在监管介入调查中股票停牌，前路未卜。证监会表示，调查仍在进行中，暂不作进一步评论。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-09-11/doc-inirmfea2271775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCE","IPOS","BK4127","REDS","159992","MEDX","BK1574","LNGR","BK1161","FRHC","06978","IBBQ","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511370?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","IBBQ","BK1574","MEDX","06978","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104990066","title":"歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1104990066","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104990066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:13","pubTimestamp":1789081985,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（1477.HK）于9月11日宣布，其核心在研产品OT-301（NCX 470，比马前列素格伦诺）已获中国国家药品监督管理局（NMPA）的新药上市申请（NDA）受理。\n这一进展标志着该创新眼科药物向正式获批上市迈出关键一步。OT-301作为一款新型眼科治疗制剂，其上市申请获得受理，预示着公司有望在中国这一庞大市场中迎来新的增长契机。\n欧康维视生物表示，将继续积极推进OT-301的审评审批进程，力争早日将这一创新疗法带给中国患者。市场分析人士认为，此次NDA获受理对欧康维视生物而言，无疑是一个重要的里程碑事件，有望进一步巩固其在眼科细分领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666197555","title":"歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666197555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666197555?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:09","pubTimestamp":1789081743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-301作为降低开角型青光眼或高眼压症患者的眼内压疗法的新药上市注册申请已获中华人民共和国(中国)国家药品监督管理局药品审评中心受理，并获Mont Blanc试验及Denali试验的数据支持。其为一种由Nicox发明的新化学实体，旨在释放贝美前列素及一氧化氮，用于降低开角型青光眼及高眼压症患者的IOP。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519701","title":"第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519701","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081313,"startTime":"0","endTime":"0","summary":"丨2026年9月11日星期五丨NO.1爱康医疗宣布提高股东股息分派占归母净利比例9月10日，爱康医疗基于对集团未来业绩及长期发展前景的信心，宣布股东股息分派及回报计划，截至2026年12月31日止财政年度，年度股息派付比例提高至不低于归母净利润的55%；截至2027年12月31日及2028年12月31日止财政年度各年，派息比例提升至不低于归母净利润的60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113871018788.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113871018788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","PPH","09939","IE0009355771.USD","MEDX","BK4588","BK1515","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4578","IE00BJT1NW94.SGD","NVS","LU0208291251.USD","BK4585","BK4532","IE0002141913.USD","BK4007","LU0211331839.USD","LU0070302665.USD","BK1161","159938","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":6,"totalSize":348,"code":"91000000","status":"200"}]}}